Biognosys delivers industry-leading proteomics contract research services from its laboratories in Boston and Zurich.
As pioneers Data-Independent Acquisition (DIA) and targeted proteomics, we specialize in deep and scalable protein profiling and provide GCP-compliant assays for clinical studies.
Our scientific experts work closely with customers throughout the entire project from initial consultation to data interpretation.
Biognosys Discovery Proteomics enables comprehensive protein level insights to support biomarker discovery and exploratory studies.
Through integrated mass spectrometry workflows and advanced data analysis, we generate deep, quantitative proteome profiles across a wide range of biological sample types and study designs.
Learn how our discovery services help transform complex biological questions into actionable proteomic insight.
Proteomics Service / Discovery Proteomics
Proteomics Service / Discovery Proteomics
Proteomics Service / Discovery Proteomics
Proteomics Service / Discovery Proteomics
Proteomics Service / Discovery Proteomics
Proteomics Service / Discovery Proteomics
Biognosys provides targeted proteomics services delivering robust, quantitative protein measurements to support translational research and clinical trials.
Our workflows support multiplexed assays for accurate, peptide resolved quantification with high reproducibility and full analytical traceability.
For challenging low abundance biomarkers, SISCAPA based immune-enrichment enables highly sensitive and quantitative LC-MS analysis in clinically relevant matrices such as plasma, serum, CSF and tissue.
From assay design and fit for purpose validation to regulated clinical sample analysis, Biognosys acts as a single CRO partner enabling confident protein biomarker decision making.
Proteomics Service / Clinical Targeted Proteomics
Proteomics Service / Clinical Targeted Proteomics
Proteomics Service / Clinical Targeted Proteomics
Chemoproteomics bridges chemical biology and proteomics, delivering mechanistic, proteome-wide insights that accelerate hit-to-lead/lead optimization stages in small molecule drug discovery.
Since 2017, Biognosys holds the exclusive global license to LiP-MS and provides a fully industrialized platform for unbiased target deconvolution, mechanism-of-action elucidation, and selectivity profiling. LiP-MS detects drug-induced conformational changes and protein binding events directly in native proteomes, with no requirement for compound modification, affinity enrichment, or protein purification.
The result is a label-free, proteome-wide view of drug–protein interactions at peptide-level resolution, applicable across diverse biological matrices and purpose-built to support both target-based and phenotypic drug discovery programs.
Proteomics Service / Chemoproteomics
Proteomics Service / Chemoproteomics
Immunopeptidomics is the mass spectrometry-based study of peptides naturally presented by MHC/HLA molecules on the cell surface, providing a direct experimental readout of what the immune system can recognize.
Immunopeptidomics allows direct analysis of MHC presented peptides in contrast to indirect genomic or transcriptomic approaches. This makes it an essential tool in drug development, enabling neoantigen discovery for cancer vaccines and T cell therapies, immunogenicity risk assessment of biotherapeutics, and autoantigen identification in autoimmune disease.
Proteomics Service / Immunopeptidomics
Proteomics Service / Immunopeptidomics
Proteomics Service / Immunopeptidomics
Biognosys’ mass spectrometry-based Digital Proteome is one of the most comprehensive resources available for tissue specific protein expression, covering over 20 healthy and diseased tissue types from both human and preclinical species. Continuously expanded with new tissues and species, the dataset serves as a robust reference for biomarker discovery, translational research, and tissue-targeted drug development.
Proteomics Service / Data Solutions
NULISA technology is an advanced proteomic platform that combines a proprietary sequential immunocomplex capture-and-release mechanism with Next-Generation Sequencing (NGS) to enable ultra-high sensitivity and scalable multiplexing.
It achieves attomolar-level detection of protein biomarkers by dramatically reducing assay background and improving signal-to-noise, allowing precise quantification of hundreds of low-abundance proteins from small-volume biofluid samples.
Proteomics Service / NULISA
Proteomics Service / NULISA
Proteomics Service / NULISA
Proteomics Service / NULISA
Proteomics Service / NULISA
Proteomics Service / NULISA
Don’t miss out on the latest from Biognosys Group – sign up to receive the latest news, innovations, and expert insights straight to your inbox.
